Dimerix Ltd
ASX:DXB
Dimerix Ltd
Research & Development
Dimerix Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dimerix Ltd
ASX:DXB
|
Research & Development
-AU$32.4m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-61%
|
|
|
Immutep Ltd
ASX:IMM
|
Research & Development
-AU$61.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-21%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$34.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Dimerix Ltd
Glance View
Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.
See Also
What is Dimerix Ltd's Research & Development?
Research & Development
-32.4m
AUD
Based on the financial report for Jun 30, 2025, Dimerix Ltd's Research & Development amounts to -32.4m AUD.
What is Dimerix Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-61%
Over the last year, the Research & Development growth was -53%. The average annual Research & Development growth rates for Dimerix Ltd have been -31% over the past three years , -42% over the past five years , and -61% over the past ten years .
